Key result
First-line R-DA-EPOCH treatment for primary mediastinal large B-cell lymphoma achieved a 3-year progression-free survival of 92.8% (95% CI 88.1-97.7%) and overall survival of 97.2%.
Why the study?
R-DA-EPOCH was adopted internationally for primary mediastinal large B-cell lymphoma, but few large real-world studies with long-term follow-up had been published.
Population
122 adults with PMBL from 9 centres in England, Scotland and Australia
Comparison
First-line R-DA-EPOCH
Design
Multi-centre retrospective study
Follow-up
Median 3.2 years (range: 0.3 - 11.6)
Authors
Loading...
Dose-intensified regimens may reduce RT need in PMBL; leaves open survival benefit versus R-CHOP plus RT in trials.
Cohort (n=122)
Yes
Real-world data confirms that first-line R-DA-EPOCH is highly effective for primary mediastinal large B-cell lymphoma, yielding excellent 3-year progression-free and overall survival.
Santarsieri et al. (2022) conducted a cohort in Primary mediastinal large B-cell lymphoma (PMBL) (n=122). R-DA-EPOCH was evaluated on 3-year progression-free survival (95% CI 88.1-97.7). First-line R-DA-EPOCH treatment for primary mediastinal large B-cell lymphoma achieved a 3-year progression-free survival of 92.8% (95% CI 88.1-97.7%) and overall survival of 97.2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: